Cargando…

Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multi-systemic disease characterized by debilitating fatigue that is not relieved by rest. The causes of the disease are still largely unexplained, and no causative treatment is currently available. Changes in the immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutz, Lena, Rohrhofer, Johanna, Zehetmayer, Sonja, Stingl, Michael, Untersmayr, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465819/
https://www.ncbi.nlm.nih.gov/pubmed/34572574
http://dx.doi.org/10.3390/biom11091359
_version_ 1784572973662863360
author Lutz, Lena
Rohrhofer, Johanna
Zehetmayer, Sonja
Stingl, Michael
Untersmayr, Eva
author_facet Lutz, Lena
Rohrhofer, Johanna
Zehetmayer, Sonja
Stingl, Michael
Untersmayr, Eva
author_sort Lutz, Lena
collection PubMed
description Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multi-systemic disease characterized by debilitating fatigue that is not relieved by rest. The causes of the disease are still largely unexplained, and no causative treatment is currently available. Changes in the immune response are considered as fundamental in the development of ME/CFS. Thus, we aimed to evaluate the immunological profile of ME/CFS patients in a retrospective data analysis. As part of the routine workup for ME/CFS patients, a differential blood count, leukocyte subtyping, and quantification of immunoglobulins and IgG subclasses, as well as a complement analysis, was performed. Out of 262 ME/CFS patients, 64.9% had a reduction or deficiency in at least one of the listed immune parameters. In contrast, 26.3% showed signs of immune activation or inflammation. A total of 17.6% of the ME/CFS patients had an unclassified antibody deficiency, with IgG3 and IgG4 subclass deficiencies as the most common phenotypes. Reduced MBL (mannose-binding lectin) levels were found in 32% of ME/CFS patients, and MBL deficiency in 7%. In summary, the present results confirmed the relevance of immune dysfunction in ME/CFS patients underlining the involvement of a dysfunctional immune response in the disease. Thus, immune parameters are relevant disease biomarkers, which might lead to targeted therapeutic approaches in the future.
format Online
Article
Text
id pubmed-8465819
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84658192021-09-27 Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Lutz, Lena Rohrhofer, Johanna Zehetmayer, Sonja Stingl, Michael Untersmayr, Eva Biomolecules Article Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multi-systemic disease characterized by debilitating fatigue that is not relieved by rest. The causes of the disease are still largely unexplained, and no causative treatment is currently available. Changes in the immune response are considered as fundamental in the development of ME/CFS. Thus, we aimed to evaluate the immunological profile of ME/CFS patients in a retrospective data analysis. As part of the routine workup for ME/CFS patients, a differential blood count, leukocyte subtyping, and quantification of immunoglobulins and IgG subclasses, as well as a complement analysis, was performed. Out of 262 ME/CFS patients, 64.9% had a reduction or deficiency in at least one of the listed immune parameters. In contrast, 26.3% showed signs of immune activation or inflammation. A total of 17.6% of the ME/CFS patients had an unclassified antibody deficiency, with IgG3 and IgG4 subclass deficiencies as the most common phenotypes. Reduced MBL (mannose-binding lectin) levels were found in 32% of ME/CFS patients, and MBL deficiency in 7%. In summary, the present results confirmed the relevance of immune dysfunction in ME/CFS patients underlining the involvement of a dysfunctional immune response in the disease. Thus, immune parameters are relevant disease biomarkers, which might lead to targeted therapeutic approaches in the future. MDPI 2021-09-14 /pmc/articles/PMC8465819/ /pubmed/34572574 http://dx.doi.org/10.3390/biom11091359 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lutz, Lena
Rohrhofer, Johanna
Zehetmayer, Sonja
Stingl, Michael
Untersmayr, Eva
Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
title Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
title_full Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
title_fullStr Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
title_full_unstemmed Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
title_short Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
title_sort evaluation of immune dysregulation in an austrian patient cohort suffering from myalgic encephalomyelitis/chronic fatigue syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465819/
https://www.ncbi.nlm.nih.gov/pubmed/34572574
http://dx.doi.org/10.3390/biom11091359
work_keys_str_mv AT lutzlena evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome
AT rohrhoferjohanna evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome
AT zehetmayersonja evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome
AT stinglmichael evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome
AT untersmayreva evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome